Here is the design of a clinical trial:

Official Title: EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial

Included conditions:
- Post Traumatic Stress Disorder
- Intensive Care Psychiatric Disorder
- Anxiety Disorders
- Depression
- Critical Care
- COVID

Study Armgroups:
- {'label': 'EMDR R-TEP intervention', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.', 'interventionNames': ['Other: Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol']}
- {'label': 'Standard care', 'type': 'NO_INTERVENTION', 'description': 'Patients will receive standard post-hospital discharge care.'}

Interventions:
- {'type': 'OTHER', 'name': 'Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol', 'description': 'EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.', 'armGroupLabels': ['EMDR R-TEP intervention']}

Primary Outcomes:
- {'measure': 'Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints', 'description': 'Feasibility will be determined by the following measures:\n\n1. Able to recruit \\>30% of eligible patients approached\n2. Complete early EMDR intervention programme in 75% or more of trial participants randomised to intervention.\n3. Protocol adherence\n4. Assignment of causality of serious events will be assessed by the chief investigator. Events attributable to trial procedures will be reviewed by trial management board, study sponsor and the research ethics committee, in order to determine ongoing feasibility.\n5. Outcome measures completed in 75% or more of trial participants', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
25% mortality/loss to follow-up.
Numbers to be randomised (sample size)
          This is a feasibility study, the results of which will be used to power a definitive study if appropriate. We anticipate a 25% mortality /loss to follow-up. A total of 26 patients will be recruited to this study, 13 patients in each arm.